Holen Sie sich die Stockscreener-App
14.76
1.20%
-0.18
Handel nachbörslich:
14.74
-0.02
-0.14%
Schlusskurs vom Vortag:
$14.94
Offen:
$14.95
24-Stunden-Volumen:
10.57M
Relative Volume:
1.11
Marktkapitalisierung:
$9.98B
Einnahmen:
$6.55B
Nettoeinkommen (Verlust:
$-551.40M
KGV:
-18.26
EPS:
-0.8082
Netto-Cashflow:
$438.90M
1W Leistung:
-5.45%
1M Leistung:
+2.07%
6M Leistung:
+94.47%
1J Leistung:
+20.59%
1-Tages-Spanne:
$14.72
$15.14
1-Wochen-Bereich:
$14.72
$16.05
52-Wochen-Spanne:
$7.265
$16.05
Avantor Inc Stock (AVTR) Company Profile
Firmenname
Avantor Inc
Sektor
Telefon
(610) 386-1700
Adresse
RADNOR CORPORATE CENTER, BUILDING ONE, RADNOR, PA
Compare AVTR vs ISRG, BDX, RMD, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTR
Avantor Inc
|
14.76 | 10.10B | 6.55B | -551.40M | 438.90M | -0.8082 |
ISRG
Intuitive Surgical Inc
|
398.30 | 142.05B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
182.52 | 49.85B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
222.30 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
65.39 | 31.71B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.30 | 30.21B | 29.14B | 1.07B | 1.05B | 1.1956 |
Avantor Inc Stock (AVTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-17 | Herabstufung | Jefferies | Hold → Underperform |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-08-01 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-29 | Herabstufung | Goldman | Buy → Neutral |
| 2025-04-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-04-28 | Herabstufung | Stifel | Buy → Hold |
| 2025-04-28 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-11 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-07-31 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-21 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-10-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-09-14 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-09-09 | Herabstufung | Cleveland Research | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-30 | Fortgesetzt | Raymond James | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-08-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-04 | Eingeleitet | Goldman | Buy |
| 2021-04-29 | Hochstufung | Stifel | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-08-02 | Eingeleitet | Cleveland Research | Neutral |
| 2019-06-14 | Eingeleitet | Janney | Buy |
| 2019-06-12 | Eingeleitet | Raymond James | Outperform |
| 2019-06-11 | Eingeleitet | Goldman | Buy |
| 2019-06-11 | Eingeleitet | Guggenheim | Buy |
| 2019-06-11 | Eingeleitet | JP Morgan | Overweight |
| 2019-06-11 | Eingeleitet | Jefferies | Buy |
| 2019-06-11 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-06-11 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-11 | Eingeleitet | SunTrust | Buy |
| 2019-06-11 | Eingeleitet | UBS | Buy |
| 2019-06-11 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Avantor Inc Aktie (AVTR) Neueste Nachrichten
Form 4 Avantor Inc For: 23 September By Investing.com - Investing.com Canada
At $16.61 a share, Avantor (AVTR) grants its CFO options that begin vesting in 2027. - Stock Titan
[Form 3] Avantor, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avantor, Inc. (AVTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
How Avantor’s New CFO Appointment At Avantor (AVTR) Has Changed Its Investment Story - Yahoo Finance
Avantor Appoints Todd Garner as New Chief Financial Officer - The Globe and Mail
Avantor stock reacts as new CFO Todd Garner steps in - AD HOC NEWS
Form 8K Avantor Inc For: 21 September By Investing.com - Investing.com Nigeria
Avantor (NYSE: AVTR) Appoints Todd Garner as CFO with $700K Salary and $1.5M Equity Award - Kalkine Media
Avantor Appoints Todd Garner as Executive Vice President and CFO with Detailed Compensation Package - Kalkine Media
Are Medical Stocks Lagging Avantor (AVTR) This Year? - Yahoo Finance
Avantor Names Todd Garner CFO to Lead Global Finance Organization - citybiz
Avantor names Todd Garner as chief financial officer By Investing.com - Investing.com Australia
Avantor Appoints New Chief Financial Officer - TradingView
Avantor, Inc. Appoints Todd Garner as Executive Vice President Effective September 21, 2026 - marketscreener.com
Avantor (AVTR) hires new CFO with seven-figure stock grants - Stock Titan
Avantor Names Todd Garner as CFO - Yahoo Finance
Avantor names Todd Garner as new CFO to lead gl... - Pluang
Avantor names Todd Garner as chief financial officer - Investing.com
Avantor appoints new Chief Financial Officer - AOL.ca
Avantor (AVTR) Appoints New Chief Financial Officer - TradingView
Avantor, Inc. (AVTR) Stock Analysis: Navigating Opportunities In The Healthcare Sector - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avantor, Inc. (AVTR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Avantor, Inc. (AVTR) Just Flashed Golden Cross Signal: Do You Buy? - Eastern Progress
Avantor Stock Price Forecast. Should You Buy AVTR? - StockInvest.us
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC - Your Wyoming Link
Avantor expands RIM single-use portfolio of bioprocessing solutions across APAC - BioSpectrum Asia
Avantor Inc stock hits 52-week high at 15.94 USD - Investing.com
Avantor Inc stock hits 52-week high at 15.94 USD By Investing.com - Investing.com India
Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Avantor, Inc. (NYSE:AVTR) Expands RIM Single-Use Portfolio Across APAC - TradingView
Here's Why You Should Add Avantor Stock to Your Portfolio for Now - Zacks Investment Research
Avantor Stock Has Strong Technical Momentum, But Make Sure Your Stop Losses Are Tight - Yahoo Finance
Avantor, Inc. (AVTR) Stock Analysis: Navigating a Competitive Healthcare Landscape with Cautious Optimism - DirectorsTalk Interviews
ETFs Investing in Avantor, Inc. Stocks - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(AVTR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avantor, Inc. (AVTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Avantor, Inc. (AVTR) Stock Analysis: Navigating the Healthcare Landscape with a Forward P/E of 16.98 - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avantor, Inc. (AVTR) And Encourages Investors to Reach Out - ACCESS Newswire
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avantor, Inc. (AVTR) And Encourages Investors to Reach Out | NYSE:AVTR | Press Release - Stockhouse
Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Avantor stock gains as investors focus on recent earnings and valuation - AD HOC NEWS
Avantor Q2 Earnings Beat Estimates on VWR Growth, Guidance Raised - Eastern Progress
Is It Too Late to Buy Avantor Inc (AVTR) After 3.2% Rally? GF Va - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Avantor, Inc. (AVTR) And Encourages Stockholders to Connect - ACCESS Newswire
Avantor, Inc. (AVTR) Stock Analysis: Evaluating Its Modest Growth Potential Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Avantor Inc. (AVTR) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report? - Yahoo Finance
Avantor: Smaller Green Shoots Of Organic Growth Returning Are Well Priced In - Seeking Alpha
Finanzdaten der Avantor Inc-Aktie (AVTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):